---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019162"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:16:09.203145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q1 net loss widens to $38.6M; cash $220.3M, runway into 2025; AdvSM trial expands

## Summary
- Cash and marketable securities $220.3M at March 31, 2023, down from $259.3M at Dec 31; funding expected into 2025.
- Net loss of $38.6M for Q1 2023 vs $30.6M in Q1 2022; R&D expenses $36.0M (+41% YoY) driven by clinical trials.
- Initiated Part 2 of Phase 2 APEX trial in Advanced Systemic Mastocytosis at 150 mg; enrollment target by end-2024.
- FDA granted Orphan Drug Designation for bezuclastinib in mastocytosis (including SM); ~30,000 annual US diagnoses.
- Upcoming data: PEAK GIST lead-in safety/efficacy at ASCO June 2023; SUMMIT NonAdvSM and APEX Part 1 data in 2H 2023.

## SEC filing metadata
- accession: 0000950170-23-019162
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017023019162/0000950170-23-019162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017023019162/cogt-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019162
- JSON: https://secwatch.observer/filing/0000950170-23-019162.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019162.txt

## Key facts
- Earnings Releases
  Cogent Biosciences, Inc. reported the first quarter ended March 31, 2023 results: net income $38.6 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: $38.6 million
  - Result: reported results
  source text: Net loss was $38.6 million for the first quarter of 2023 compared to a net loss of $30.6 million for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000095017023019162/0000950170-23-019162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.